Literature DB >> 2485208

Anti-peptide antibodies recognize anti-substance P antibodies in an idiotypic fashion.

D W Pascual1, K L Bost.   

Abstract

A peptide (AGFGVVKKPNY) was synthesized based on an RNA sequence complementary to the mRNA encoding substance P (Sub P). Antibodies against this Sub P complementary peptide (termed anti-C Pep antibodies) were produced by immunizing rats with peptide conjugated to the carrier protein, keyhole limpet hemocyanin. Antisera were then passed over a peptide conjugated affinity column to specifically purify the anti-C Pep antibodies. In a similar manner, anti-Sub P antibodies were produced in rabbits and made monospecific by affinity chromatography. Using a radioimmunoassay, 125I-anti-C Pep antibodies were found to bind anti-Sub P antibodies in a dose-dependent fashion. Control antibodies did not bind nor did they inhibit binding, suggesting that the interaction of the affinity purified antibodies was not due to the presence of constant region determinants. Ultimately, the idiotypic-anti-idiotypic nature of the anti-Sub P and anti-C Pep antibodies was demonstrated using a radioimmunoassay for Sub P. Anti-C Pep antibodies competed like unlabeled Sub P in the ability to block 125I-Tyr8-Sub P binding to anti-Sub P antibodies, whereas control antibodies did not. We concluded, therefore, that immunizing with this pair of complementary peptides (i.e., Sub P and C Pep) generates antibodies which are anti-idiotypic.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2485208

Source DB:  PubMed          Journal:  Pept Res        ISSN: 1040-5704


  4 in total

1.  Limited interleukin-18 response in Salmonella-infected murine macrophages and in Salmonella-infected mice.

Authors:  A Elhofy; K L Bost
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

2.  Substance P production by P388D1 macrophages: a possible autocrine function for this neuropeptide.

Authors:  D W Pascual; K L Bost
Journal:  Immunology       Date:  1990-09       Impact factor: 7.397

3.  Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor.

Authors:  S Araga; R D LeBoeuf; J E Blalock
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

4.  In vivo treatment with anti-interleukin-13 antibodies significantly reduces the humoral immune response against an oral immunogen in mice.

Authors:  K L Bost; R H Holton; T K Cain; J D Clements
Journal:  Immunology       Date:  1996-04       Impact factor: 7.397

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.